Entry of Burkholderia organisms into respiratory epithelium: CFTR, microfilament and microtubule dependence.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Jane B TaylorCarolyn L Cannon

Abstract

The pathogenesis of infection with Burkholderia cepacia complex (Bcc) organisms may be linked to its capacity to invade respiratory epithelium. An antibiotic exclusion assay was used to study B. dolosa AU4459 and B. cenocepacia J2315 invasion into wild-type (WT) and CFTR-deficient respiratory epithelial cells. Inhibitors were used to evaluate Bcc invasion dependency on host microtubule (mt) and microfilament (mf) systems. B. dolosa entered WT-CFTR cells with 5-fold greater efficiency than CFTR deficient cells (25% vs 5%, respectively). Invasion dropped to <0.5% after either mf or mt inhibition. B. cenocepacia entered WT (0.05%) and CFTR-deficient cells (0.07%) with similarly low efficiencies, which significantly decreased with either mf or mt inhibition (0.008% and 0.002%, respectively). B. dolosa and B. cenocepacia enter respiratory epithelial cells in a mf and mt dependent fashion. Mutated CFTR leads to less internalization of B. dolosa, but not B. cenocepacia.

References

Jan 1, 1994·American Journal of Respiratory Cell and Molecular Biology·A L CozensD C Gruenert
Aug 1, 1994·The Pediatric Infectious Disease Journal·J J LipumaT L Stull
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T A OelschlaegerD J Kopecko
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·E R LazarowskiR C Boucher
Oct 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·G B PierT S Zaidi
Feb 24, 2001·Cellular Microbiology·G Tran Van NhieuP J Sansonetti
Jul 11, 2001·Journal of Medical Microbiology·C H ChiuD P Speert
Aug 9, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·J J LiPuma
Sep 28, 2001·Journal of Clinical Microbiology·T CoenyeJ J LiPuma
Oct 6, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E MahenthiralingamD P Speert
May 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Torsten H SchroederGerald B Pier
Apr 10, 2004·Science·Pascale Cossart, Philippe J Sansonetti
May 15, 2004·International Journal of Systematic and Evolutionary Microbiology·Karen VermisPeter Vandamme
Nov 8, 2005·American Journal of Respiratory and Critical Care Medicine·Leslie A KalishDonald Goldmann
Jun 20, 2006·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Emma CaraherSiobhán McClean
Dec 17, 2008·Journal of Medical Microbiology·Siobhán McClean, Máire Callaghan

❮ Previous
Next ❯

Citations

Dec 6, 2011·Current Opinion in Microbiology·Máire Callaghan, Siobhán McClean
Dec 5, 2015·Frontiers in Cellular and Infection Microbiology·Jonathan DavidGraeme C Clark
Jul 30, 2015·Canadian Journal of Microbiology·Miguel A Valvano
Jul 5, 2016·Frontiers in Cellular and Infection Microbiology·Thibault G SanaSophie Bleves
Mar 30, 2017·Infection and Immunity·Damien RouxDeborah R Yoder-Himes
Aug 12, 2016·Genome Research·Siew Woh ChooGuat Jah Wong
Dec 6, 2016·Frontiers in Microbiology·Rahul MittalXue Z Liu
Nov 17, 2020·Frontiers in Veterinary Science·Berenice Plasencia-MuñozAlma L Guerrero-Barrera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.